title: Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.
abstract: Therapeutic antibodies have captured substantial attention due to the relatively high rate at which these products reach marketing approval, and the subsequent commercial success they frequently achieve. In the 2000s, a total of 20 antibodies (18 full-length IgG and 2 Fab) were approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA). In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011. However, a less heralded group of antibody-based therapeutics comprising proteins or peptides fused with an Fc is following the success of classical antibodies.
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
mesh_terms: D001172:Arthritis, Rheumatoid / Q000628:therapy; D002986:Clinical Trials as Topic; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000378:metabolism / Q000627:therapeutic use; D007155:Immunologic Factors / Q000378:metabolism / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use*; D011565:Psoriasis / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D007141:Immunoglobulin Fc Fragments; D007155:Immunologic Factors; D010455:Peptides; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A